Much remains unknown about the frequency of HER2-low (IHC 1+ or 2+) expression and the change of HER2 status from primary to metastatic tumor samples. There is limited data available about the HER2-low frequency in solid tumors beyond breast and gastric/gastroesophageal (GEJ) cancer.Methods: ...
Conclusions This is the first tumor-agnostic global study of T-DXd in a broad range of HER2-expressing solid tumors. T-DXd showed encouraging ORR, particularly in pts with IHC 3+ expression, durable clinical benefit, and a...
4.Pillai R, et al. HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium. Cancer. 2017;1;123(21): 4099-4105. 5.Yan M, et al. HER2 expression status in diverse cancers: review of results from 37,992 patients. Cancer Metastasis Rev. 2015 Mar;34(1):...
[2] Zaman S, Jadid H, Denson AC, Gray JE. Targeting Trop-2 in solid tumors: future prospects. Onco Targets Ther. 2019 Mar 1;12:1781-1790. [3] Neelima Vidula, Christina Yau, Hope S. Rugo. Trop2 gene expre...
et al. Macrophage infiltration and heme oxygenase-1 expression correlate with angiogenesis in human gliomas. Clin. Cancer Res. 5, 1107–1113 (1999). CAS PubMed Google Scholar Torisu, H. et al. Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: ...
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment ...
et al. Preclinical activity of HER2-selective tyrosine kinase inhibitor tucatinib as a single agent or in combination with trastuzumab or docetaxel in solid tumor models. Mol. Cancer Ther. 19, 976–987 (2020). Article CAS Google Scholar Dinkel, V. et al. ARRY-380, a potent, small ...
11. Banerji U, van Herpen CML, Saura C, Thistlethwaite F, Lord S, Moreno V, et al. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol 2019; 20(8):1124-1135. ...
Rack B, Zombirt E, Trapp E et al (2016) Comparison of HER2 expression in primary tumor and disseminated tumor cells in the bone marrow of breast cancer patients. Oncology 90:232–238 Article CAS PubMed Google Scholar Kramer-Marek G, Oyen WJ (2016) Targeting the human epidermal growth fa...
Dr Davila on the Clinical Implications of Tumor Driver and Immune Escape Research in LBCL Dr Ruella on the Importance of Clinical Trial and Treatment Accessibility for Myeloma Dr Cortese on the Benefits of a Multiomic Evaluation of Immunologic Changes in CLL After Venetoclax...